John Oyler, BeiGene CEO (Endpoints News, PharmCube)
December 20, 2021 07:37 AM ESTUpdated 10:22 AM
Deals
China

No­var­tis turns to BeiGene again for the next big check­point tar­get, pay­ing $300M to jump in­to TIG­IT race

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Take­da an­nounces hand­ful of pipeline cuts in ef­fort to ‘piv­ot re­sources’

GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es

AI-fo­cused biotech in­sitro cuts 22% of staff, cit­ing 'tu­mul­tuous mar­ket'

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times